智通财经APP讯，艾美疫苗(06660)发布公告，黄沛翘女士(黄女士)已提呈辞任本公司联席公司秘书(联席公司秘书)， 自 2025年12月31日起生效。
另一位联席公司秘书刘灵女士(刘女士)近期已获联交所确认，其符合联交所证券上市规则(上市规则)第 3.28条规定担任本公司公司秘书的资格，故无需进一步豁免。于黄女士辞任后，刘女士将继续留任并担任本公司唯一公司秘书，自2025年12月31日起生效。
黄女士于辞任联席公司秘书后，亦已根据上市规则第3.05条的规定辞任本公司授权代表(授权代表)。董事会宣布，刘女士已获委任为授权代表，以接替黄女士，自2025年12月31日起生效。执行董事周延先生将继续担任另一授权代表。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.